EMBRYO DEVELOPMENT CORP
8-K, 1998-02-05
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: CULLIGAN WATER TECHNOLOGIES INC, S-8, 1998-02-05
Next: GLOBAL TELESYSTEMS GROUP INC, S-8, 1998-02-05



               SECURITIES AND EXCHANGE COMMISSION
                                
                    Washington, D.C.  20549
                    -----------------------                                 
                         
                                
                            FORM 8-K
                                
                         CURRENT REPORT
                                
               Pursuant to Section 13 or 15(d) of
              the Securities Exchange Act of 1934
                                
                                
 Date of Report (Date earliest event reported) January 21, 1998
                                
                 EMBRYO DEVELOPMENT CORPORATION    
    (exact name of registrant as specified in its charter) 
                                
                                
                           DELAWARE                          
         (State or other jurisdiction of incorporation)
                                
                                
     0-27028                                  13-3832099             
_____________________________________________________________________   
(Commission File Number)                (IRS Employer Identification 
                                                      Number)
                                
                                
 750 Lexington Avenue, Suite 2750, New York, NY     10022       
_____________________________________________________________________
(Address of principal executive offices)          (Zip Code)
                                
                                
                                
Registrant's Telephone Number, Including Area Code:(212) 355-8484
                                
                                                               
        (Former name or former address, if changed since last
                            report)


Item 5.   Other Events.
______   ________________

     On January 21, 1998, Hydrogel Design Systems, Inc. ("HDS") (a
company in which Embryo Development Corporation has an equity
interest) entered into a Settlement Agreement (the "Agreement")
with John and Janice Essmyer settling in all regards its
outstanding litigation.  In connection with the Agreement, the
Essmyer's received a cash payment of $450,000 and a promissory note
from HDS in the amount of $950,000 which is due and payable upon
the earlier of the (a) initial public offering of securities of
HDS, (b) completion of a private financing by HDS in the aggregate
amount of at least $4,000,000, (c) the sale or transfer of all, or 
substantially all of the assets of HDS, or (d) January 10, 2002. 
In addition, the Essmyers surrendered their rights to the 150,000
shares of Embryo Common Stock formerly granted to them and John
Essmyer surrendered the 250,000 shares of HDS Common Stock formerly
issued to him.  Further, the Agreement provides that the Essmyer's
will resume the sale of apnea monitoring equipment through 
Alternative Designs Systems, Inc. (an entity controlled by the
Essmyers') and HDS will immediately satisfy all outstanding
payables incurred since February 6, 1997 with respect to
Alternative Design Systems, Inc. vendors while  retaining all
accounts receivables and all inventory as of December 15, 1997.

     On January 21, 1998, the Company's equity interest in HDS,
which previously represented a 50.04% majority common interest and
92.9% voting interest, was reduced to 41.8% common ownership as a
result of the Company surrendering all 15,000,000 shares of voting
Preferred Stock in exchange for 21,500 shares of Common Stock. The
exchange was done at the request of certain third party investors
of a Private Placement by HDS, under which HDS issued approximately
475,000 additional common shares. As of February 2, 1998, these
transactions resulted in the Company retaining approximately 41.8%
of the Common Stock of HDS. If the Private Placement is fully
subscribed, the Company's ownership will decrease to approximately
35.6% upon completion of the Private Placement.

     As a result of the surrender of the voting Preferred Stock and
the issuance of additional Common Stock, the Company's ownership in
HDS was reduced to below 50% interest and therefore, the assets,
liabilities and operations of HDS after January 21, 1998 will not
be included in the financial statements of the Company.




Item 7.   Financial Statements and Exhibits     
______    __________________________________

(a)  Financial Statements of Business Acquired - Not applicable.

(b)  Pro Forma Financial Information

     The following unaudited pro forma condensed financial
statements are filed with this report:

Pro Forma Condensed Balance Sheet as of October 31, 1997...Page F-1
Pro Forma Condensed Statements of Operations:
     Year Ended April 30, 1997.............................Page F-2
     Six Months Ended October 31, 1997.....................Page F-3

     The Pro Forma Condensed Balance Sheet of Registrant as at
October 31, 1997 reflects the financial position of Registrant
after giving effect to the Company's reduced ownership of HDS to
below 50% as discussed in Item 5. and assumes the transaction took
place on October 31, 1997.  The Pro Forma Condensed Statements of
Operations for the fiscal year ended April 30, 1997 and the six
months ended October 31, 1997 assume that the disposition occurred
on October 3, 1996 (inception of HDS), and are based on the
operations of the Registrant for the year ended April 30, 1997 and
the six months ended October 31, 1997.

     The unaudited pro forma condensed financial statements have
been prepared by the Registrant based upon assumptions deemed
proper by it.  The unaudited pro forma condensed financial
statements presented herein are shown for illustrative purposes
only and are not necessarily indicative of the future financial
position or future results of operations of Registrant, or of the
financial position or results  of operations of Registrant that
would have actually ocurred had the transaction been in effect as
of the date or for the periods presented.  In addition, it should
be noted that Registrant's financial statements will reflect the
transaction only from January 21, 1998, the Closing Date of the
Private Placement.

     The unaudited pro forma condensed  financial statements should
be read in conjunction with the historical financial statements and
related notes of Registrant.
  
(c)    Exhibits - None.

                       
                              
                                
                                
                                
                                
                                
                                
                           SIGNATURES



          Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly authorized and caused the
undersigned to sign this Report on the Registrant's behalf.


                         
                         EMBRYO DEVELOPMENT CORPORATION



                         By:   /s/ Matthew Harriton     
                              _____________________
                              Matthew Harriton
                              President


Dated:   February 2, 1998


 


































                 PRO FORMA FINANCIAL INFORMATION
                 ________________________________               
         EMBYRO DEVELOPMENT CORPORATION AND SUBSIDIARY
                 (A Development Stage Company)
               PRO FORMA CONDENSED BALANCE SHEET 
                      AT OCTOBER 31, 1997
                          (Unaudited)

<TABLE>
                                                (a)  
                                             Pro Forma 
                                  Historical Adjustments Proforma 
                                  __________ ___________ ________
<S>                             <C>         <C>          <C>                 
     Assets

CURRENT ASSETS:
 Cash and cash equivalents      $  456,267  $ 226,145  $ 230,122 
 Investment in available-for-sale
   securities                      299,765        -0-    299,765
 Accounts and interest receivable  119,198     99,353     19,845
 Inventories                        80,836     43,600     37,236
 Prepaid expenses and other
   current assets                  219,382     33,050    186,332
 Due from affiliate                    -0-   (106,002)   106,002
                                 _________   ________    _______
   Total current assets          1,175,448    296,146    879,302

INVESTMENTS IN AVAILABLE-FOR-SALE
  SECURITIES                       250,000        -0-    250,000

PROPERTY, PLANT & EQUIPMENT, NET 1,714,234  1,697,634     16,600

LICENSED TECHNOLOGY, NET         1,047,975        -0-  1,047,975

INVESTMENT IN AND ADVANCES TO
  AFFILIATE                            -0- (1,038,890) 1,038,890

OTHER ASSETS                       101,645     16,848     84,797
                                __________ __________ __________
                                $4,289,302 $  971,738 $3,317,564
                                =========  ========== ==========

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
 Accounts payable and accrued
   expenses                       $686,064 $  459,571 $  226,493
 Note payable                      350,000    350,000        -0-
                                 __________ __________ __________ 
   Total current liabilities     1,036,064    809,571    226,493

NOTE PAYABLE                       600,000    600,000        -0-
                                 _________  _________  __________
   Total liabilities             1,636,064  1,409,571    226,463
   Total stockholders' equity    2,653,238   (437,833) 3,091,071
                                 _________  _________ ___________
                                $4,289,302  $ 971,738 $3,317,564 
                                ==========  ========= ===========
(a) To eliminate the assets and liabilities of HDS included in
the consolidated balance sheet as of October 31, 1997 and to
reflect the Company's 41.84% equity interest in HDS as of October
31, 1997.
</TABLE>
                              F-1
         
             PRO FORMA FINANCIAL INFORMATION
             _______________________________                        
         EMBYRO DEVELOPMENT CORPORATION AND SUBSIDIARY
                 (A Development Stage Company)
          PRO FORMA CONDENSED STATEMENT OF OPERATIONS
               FOR THE YEAR ENDED APRIL 30, 1997
                          (Unaudited)

<TABLE>
                                                (a)  
                                             Pro Forma 
                                  Historical Adjustments Proforma 
                                  __________ ___________ _________          
     
<S>                             <C>        <C>         <C>

REVENUES                        $ 287,487  $ 115,307   $ 172,180 
                                ---------  ---------   ---------
COSTS AND EXPENSES:
   Cost of sales                  237,839    106,319     131,520
   General and administrative   1,814,174    285,623   1,528,551
   Research and development       185,678        -0-     185,678
   Amortization                   230,000        -0-     230,000  
   Equity in operations of 
    affiliate                         -0-   (116,468)    116,468
   Interest (income) expense     (133,729)     1,731    (135,460)
                                __________ _________  ___________
                                2,333,962    277,205   2,056,757 

LOSS BEFORE MINORITY INTEREST  (2,046,475)  (161,898) (1,884,577)

MINORITY INTEREST IN NET
   LOSS OF SUBSIDIARY             139,072    139,072         -0- 
                               __________  _________  ___________                               
NET LOSS                      $(1,907,403)  $(22,826)$(1,884,577)
                              ===========  ========= ============
NET LOSS PER SHARE             $     (.40) $     .00 $      (.40)
                              ===========  ========= ============

WEIGHTED AVERAGE NUMBER OF
 SHARES OF COMMON STOCK
 OUTSTANDING                    4,728,274  4,728,274    4,728,274
                               ==========  ========= ============ 


(a) To eliminate the operations of HDS for the period of
inception (October 3, 1996) to April 30, 1997 and to reflect the
Company's 41.84% share of the loss as if the transaction had been
completed on October 3, 1996.
                                
</TABLE>
                                
                                
                                
                                
                                
                                
                               F-2



                PRO FORMA FINANCIAL INFORMATION
                _______________________________                                
         EMBYRO DEVELOPMENT CORPORATION AND SUBSIDIARY
                 (A Development Stage Company)
          PRO FORMA CONDENSED STATEMENT OF OPERATIONS
           FOR THE SIX MONTHS ENDED OCTOBER 31, 1997
                          (Unaudited)
                                   
<TABLE>
  
                                              (a)  
                                             Pro Forma 
                                  Historical Adjustments Proforma 
                                  __________ ___________ ________                 
     

<S>                             <C>        <C>         <C>
REVENUES                        $ 569,521  $ 493,752   $  75,769 
                                ---------  ---------   ----------
COSTS AND EXPENSES:
   Cost of sales                  460,382    397,983      62,399
   General and administrative     984,892    332,350     652,542
   Royalties                       57,752        -0-      57,752
   Research and development        87,977        -0-      87,977
   Amortization                   115,000        -0-     115,000  
   Equity in operations of 
    affiliate                         -0-   (119,956)    119,956
   Interest (income) expense        5,675     50,121     (44,446)
                                _________  _________   __________
                                1,711,678    660,498   1,051,180 

LOSS BEFORE MINORITY INTEREST  (1,142,157)  (166,746)   (975,411)

MINORITY INTEREST IN NET
   LOSS OF SUBSIDIARY              65,881     65,881         -0- 
                              ___________  __________  __________                                                                  
NET LOSS                      $(1,076,276) $(100,865)$  (975,411)
                              ===========  ========= ============
NET LOSS PER SHARE             $     (.22) $    (.02)$      (.20)
                              ===========  ========= ============ 

WEIGHTED AVERAGE NUMBER OF
 SHARES OF COMMON STOCK
 OUTSTANDING                    4,845,000  4,845,000    4,845,000
                              ===========  ==========  ========== 



(a) To eliminate the operations of HDS for the entire period and
to reflect the Company's 41.84% share of the loss as if the
transaction had been completed on October 3, 1996.
                                
                                
                                
</TABLE>
                                
                                
                                
                                
                               F-3


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission